150 related articles for article (PubMed ID: 9036892)
1. The potential role of fecal carbonic anhydrase II in screening for colorectal cancer.
Yokoyama S; Shatney CH; Mochizuki H; Hase K; Johnson DL; Cummings S; Trollope ML; Tamakuma S
Am Surg; 1997 Mar; 63(3):243-6; discussion 246-7. PubMed ID: 9036892
[TBL] [Abstract][Full Text] [Related]
2. Transferrin dipstick as a potential novel test for colon cancer screening: a comparative study with immuno fecal occult blood test.
Sheng JQ; Li SR; Wu ZT; Xia CH; Wu X; Chen J; Rao J
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2182-5. PubMed ID: 19661074
[TBL] [Abstract][Full Text] [Related]
3. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
Takai T; Kanaoka S; Yoshida K; Hamaya Y; Ikuma M; Miura N; Sugimura H; Kajimura M; Hishida A
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1888-93. PubMed ID: 19505922
[TBL] [Abstract][Full Text] [Related]
4. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
5. [Detection of protein p53 in the stool of patients with colorectal cancer].
Jaïs P; Kapel N; Chosidow D; Rupaire N; Rougier P; Lasser P; Mignon M; Lewin MJ; Gobert JG
Gastroenterol Clin Biol; 1997; 21(10):754-9. PubMed ID: 9587516
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of calgranulin B in stools from the patients with colorectal cancer.
Yoo BC; Shin YK; Lim SB; Hong SH; Jeong SY; Park JG
Dis Colon Rectum; 2008 Nov; 51(11):1703-9. PubMed ID: 18584251
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
8. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
Mizuno M; Mizuno M; Iwagaki N; Nasu J; Okazaki H; Yamamoto K; Okada H; Tsuji T; Fujita T; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2550-5. PubMed ID: 14638362
[TBL] [Abstract][Full Text] [Related]
9. Fecal protein markers of colorectal cancer.
Dubrow R; Yannielli L
Am J Gastroenterol; 1992 Jul; 87(7):854-8. PubMed ID: 1615938
[TBL] [Abstract][Full Text] [Related]
10. Fecal lysozyme: an unreliable marker for colorectal cancer.
Dubrow R; Kim CS; Eldred AK
Am J Gastroenterol; 1992 May; 87(5):617-21. PubMed ID: 1595650
[TBL] [Abstract][Full Text] [Related]
11. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
12. Colon cancer screening strategies.
Agrawal J; Syngal S
Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
[TBL] [Abstract][Full Text] [Related]
13. Lower specificity of occult-blood test on stool collected by digital rectal examination.
Zhang B; Nakama H; Fattah AS; Kamijo N
Hepatogastroenterology; 2002; 49(43):165-7. PubMed ID: 11949640
[TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydorase isoenzyme I (CA-I) concentration in feces and urine as a temporary marker of occult blood in beagle dogs.
Iguchi K; Kawato K; Seita T; Kuribayashi T; Shimada T; Matsumoto M; Yamamoto Y; Yamada M; Yamamoto S
Exp Anim; 2007 Jan; 56(1):43-9. PubMed ID: 17283890
[TBL] [Abstract][Full Text] [Related]
15. [Screening test for colorectal cancer. Practical experiences with fecal testing for occult blood. 2: Rate of a false-negative occult blood test].
Schellenberger U; Raabe A; Erler K
Z Arztl Fortbild (Jena); 1987; 81(20):1057-9. PubMed ID: 3433823
[No Abstract] [Full Text] [Related]
16. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
17. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers.
Karl J; Wild N; Tacke M; Andres H; Garczarek U; Rollinger W; Zolg W
Clin Gastroenterol Hepatol; 2008 Oct; 6(10):1122-8. PubMed ID: 18928937
[TBL] [Abstract][Full Text] [Related]
18. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen.
Kim Y; Lee S; Park S; Jeon H; Lee W; Kim JK; Cho M; Kim M; Lim J; Kang CS; Han K
Ann Clin Lab Sci; 2003; 33(1):32-8. PubMed ID: 12661896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
